The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer

HER2+/HR+ breast cancer is a special molecular type of breast cancer. Existing treatment methods are prone to resistance; “precision treatment” is necessary. Pyrotinib is a pan-her kinase inhibitor that can be used in HER2-positive tumors, while SHR6390 is a CDK4/6 inhibitor that can inhibit ER+ bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yukun, Yuan, Xiang, Li, Jing, Liu, Zhiwei, Li, Xinyang, Wang, Ziming, Wei, Limin, Li, Yuanpei, Wang, Xinshuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716872/
https://www.ncbi.nlm.nih.gov/pubmed/34977029
http://dx.doi.org/10.3389/fcell.2021.785796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716872/
https://www.ncbi.nlm.nih.gov/pubmed/34977029
http://dx.doi.org/10.3389/fcell.2021.785796

Ejemplares similares